ConvergeHEALTH by Deloitte Announces Landmark Collaboration with Moffitt Cancer Center/M2Gen
ConvergeHEALTH, M2Gen and Deloitte will offer personalized medicine studies and real-world analytics services to life sciences organizations, study sponsors and cancer centers
NEW YORK, April 1, 2014 /PRNewswire/ -- ConvergeHEALTH by Deloitte is announcing that M2Gen, a wholly-owned subsidiary of Moffitt Cancer Center, has joined its real-world evidence and analytics consortium to help transform cancer care around the use of personalized medicine.
M2Gen joins the consortium initiated by Intermountain Healthcare and ConvergeHEALTH to contribute toward biomarker discovery, gene-based clinical trial matching and real-world evidence generation to support the shift to personalized medicine in oncology.
M2Gen has one of the world's richest sources of oncology and personalized medicine insights as a result of Moffitt Cancer Center's Total Cancer Care® program. Total Cancer Care helps researchers and caregivers address the needs of cancer patients and their families throughout their lifetimes and into future generations. Patients donate information and tissue that is analyzed by M2Gen, building a repository of clinical and molecular data that can provide insights into biomarkers, accelerate targeted gene-based clinical trials and support real-world evidence for optimal treatments in populations.
Together, ConvergeHEALTH, M2Gen and Deloitte will support life sciences and health care organizations worldwide in advancing best learnings around translational research, real-world evidence and personalized medicines. It will also leverage ConvergeHEALTH's OutcomesMiner solution suite, informatics and consulting services with the experiences of M2Gen and Moffitt in conducting personalized medicine studies.
"Our Total Cancer Care protocol has transformed the approach through which data is collected and appropriately used to identify and bring new personalized treatment options to patients," said Bill Dalton, Ph.D., M.D., chief executive officer of M2Gen and director of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center. "We are thrilled to team with Deloitte to extend our reach and bring our combined analytics and collaborative study services to clients around the world. This will expand the studies we will conduct, bringing more therapies to market and provide more studies to the health systems we serve."
"ConvergeHEALTH was launched to accelerate the transformation of health care to a more personalized, value based system," added Brett Davis, principal, Deloitte Consulting LLP and general manager for ConvergeHEALTH by Deloitte. "We are excited to team with M2Gen as a global leader in personalized medicine to provide the solutions to our health care and life sciences clients to make this vision a reality. Our OutcomesMiner platform, combined with M2Gen's expertise, informatics experience and unique data, will support innovation in oncology to the ultimate benefit of patients."
"We believe our collaboration with ConvergeHEALTH has the potential to accelerate our ability to bring the best research successes to our patients," said Alan F. List, M.D., president and CEO of Moffitt Cancer Center. "Through our data on biomarkers and ConvergeHEALTH's analytics, this collaboration will help us work toward our goal of personalized cancer care for our patients."
Nitin Mittal, principal, Deloitte Consulting LLP and executive vice president of services for ConvergeHEALTH by Deloitte, said, "The Total Cancer Care protocol combined with research informatics solutions from ConvergeHEALTH and transformative consulting services from Deloitte will help oncology centers engage patients more effectively, give back to the community, become a hub for personalized cancer treatment and participate in collaborative research with other centers globally."
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer since 1999. With more than 4,200 employees, Moffitt has an economic impact on the state of nearly $2 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.
About M2Gen®
M2Gen® is Moffitt Cancer Center's wholly owned, for-profit subsidiary advancing personalized medicine by using high quality tissue, clinical data and molecular technology to advance research for personalized cancer treatments. The goal of M2Gen is to accelerate science which will provide a foundation for personalized medicine at the point of patient care through identifying a patient's susceptibility to disease, predicting how the patient will respond to a particular drug, and matching patients to the best therapies for an optimal treatment outcome. M2Gen, along with Moffitt and 17 hospitals in a Consortium Network, has created the world's largest cancer-focused biorepository linked to clinical and molecular data. For more information, visit www.m2gen.com
About ConvergeHEALTH
ConvergeHEALTH brings powerful, demonstrated analytics platforms and data models from Recombinant by Deloitte, advanced proprietary and open source analytics, content and benchmarks through collaboration with industry leaders and deep experiences from Deloitte's Life Sciences and Health Care consulting practice to help our clients survive and thrive in the new paradigm of value-based, personalized medicine. For more information, visit www.converge-health.com.
As used in this document, "Deloitte" means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.
Copyright © 2014 Deloitte Development LLC. All rights reserved.